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FAS (also called APO-1 and CD95) and its physiological ligand, FASL, regulate apoptosis of unwanted or dangerous cells, functioning as a guardian against autoimmunity and cancer development [1] [2] [3] [4] . Distinct cell types differ in the mechanisms by which the 'death receptor' FAS triggers their apoptosis [1] [2] [3] [4] . In type I cells, such as lymphocytes, activation of 'effector caspases' by FAS-induced activation of caspase-8 suffices for cell killing, whereas in type II cells, including hepatocytes and pancreatic b-cells, caspase cascade amplification through caspase-8-mediated activation of the proapoptotic BCL-2 family member BID (BH3 interacting domain death agonist) 5 is essential [6] [7] [8] . Here we show that loss of XIAP (X-chromosome linked inhibitor of apoptosis protein ) 9 ,10 function by gene targeting or treatment with a second mitochondriaderived activator of caspases (SMAC 11 , also called DIABLO 12 ; direct IAP-binding protein with low pI) mimetic drug in mice rendered hepatocytes and b-cells independent of BID for FASinduced apoptosis. These results show that XIAP is the critical discriminator between type I and type II apoptosis signalling and suggest that IAP inhibitors should be used with caution in cancer patients with underlying liver conditions.
Hepatocytes are sensitive to FASL 13 or agonistic anti-FAS antibodies 14 , and observations of invasion of FASL-expressing cytotoxic lymphocytes into hepatic sinusoids implicated FAS-induced apoptosis as a cause of a variety of acute or chronic liver diseases 15 . Caspase-8 (ref. 16 ) and its activator FADD/MORT1 (FAS-associated death domain protein; ref. 17) are required for FAS-induced apoptosis in all cell types studied so far. Although initial studies produced conflicting results 13, 18 , it is now clear that amplification of apoptosis signalling through caspase-8-mediated activation of the BH3-only protein BID leading to BAX/BAK-dependent activation of caspase-9 and effector caspases is essential in hepatocytes and pancreatic b-cells (type II cells), but dispensable in lymphocytes (type I cells; Supplementary Fig. 1 ) [6] [7] [8] . It is unclear why FAS activates substantially different apoptotic pathways in different cell types, but it has been postulated that this may be due to differences in the extent of FAS aggregation or internalization, extent of caspase cascade activation, levels of caspase inhibitors (XIAP) and/or abundance of caspase substrates that need to be proteolysed for cells to die 4, [18] [19] [20] . To explore the differences between type I and type II cells, we compared the levels and activation of apoptosis regulators and the processing of caspase substrates between type I cells, thymocytes, and type II cells, hepatocytes, after FAS stimulation ( Supplementary Fig. 2a-c) . Processing of caspase-8 into its cleaved form (p18) could be detected as early as 15 min after FAS stimulation by immunoblotting or pull down of the active enzyme with biotinylated X-Val-Ala-Asp-fluoromethylketone (X-VAD-fmk; caspase inhibitor that binds only active caspases) followed by immunoblotting with a caspase-8-specific antibody ( Supplementary  Fig. 2a ). Caspase-8-mediated BID cleavage and activation of caspase-3 and -7 became evident by ,15 and ,60 min, respectively (Supplementary Fig. 2a, b) . Apoptosis induction was comparable in wild-type thymocytes and hepatocytes ( Supplementary Fig. 2a-c) . As reported previously 7 , FASL elicited a similar extent of apoptosis in wild-type and Bid 2/2 thymocytes in both single-cell suspension and fetal thymic organ culture (FTOC; Supplementary Fig. 2a, c) . BID-deficient thymocytes and hepatocytes exhibited normal levels of early caspase-8 activation, but BID-deficient hepatocytes showed considerably less caspase-9 activation and a complete lack of effector caspase activation ( Supplementary Fig. 2a, b) . The levels of anti-apoptotic BCL-2, BCL-X L , MCL-1 and the pro-apoptotic SMAC/DIABLO were similar in thymocytes and hepatocytes and remained largely unchanged during FAS activation ( Fig. 1a and Supplementary Fig. 2d, e) .
Notably, despite the fact that the basal levels of XIAP were comparable in both cell types, FAS stimulation affected XIAP in substantially different ways in thymocytes compared with hepatocytes. In thymocytes XIAP levels declined rapidly (Fig. 1b) , but this could be prevented by inhibition of apoptosis with the caspase blocker qVD-OPh (quinoline-Val-Asp-difluorophenoxymethylketone) ( Supplementary  Fig. 3a, b) , indicating that it is a consequence of cell death. In marked contrast, in hepatocytes treatment with FASL resulted in an increase in XIAP levels, despite efficient initiation of apoptosis (Fig. 1b) . This increase in XIAP could be blocked by addition of qVD-OPh or BID deficiency, which both prevent effector caspase activation ( Supplementary Fig. 3c, d ). Co-immunoprecipitation showed that FAS stimulation caused an increase in the amount of processed caspase-3 associated with XIAP in hepatocytes (Fig. 1c) , indicating that XIAP is stabilized by binding and inhibiting activated effector caspases. Furthermore, substantial differences in cleavage of the proto-typical effector caspase substrate ICAD (inhibitor of caspaseactivated DNase) 21, 22 were detected in thymocytes and hepatocytes. Notably, in wild-type hepatocytes ICAD processing was considerably less efficient than that in wild-type or Bid 2/2 thymocytes, and in BIDdeficient livers no ICAD cleavage could be detected (Fig. 1d, e) . Accordingly, fluorogenic (DEVDase) assays showed that FASLtreated wild-type and Bid 2/2 thymocytes had ,sixfold higher levels of effector caspase activity than wild-type hepatocytes, and no such caspase activity was detected in livers from FASL-injected Bid 2/2 mice (Fig. 1f) . These results indicate that the ratio between activated effector caspases, the caspase inhibitor XIAP and the caspase substrates that need to be proteolysed for a cell to die may determine whether cells undergo type I or type II FAS-induced apoptosis.
Therefore and because XIAP is a potent inhibitor of caspase-9 and effector caspases 9, 10 , and because XIAP overexpression delayed FAS-induced apoptosis in mouse thymocytes 23 , we explored the role of XIAP in FAS-induced hepatocyte killing in vivo. As reported previously 13, 14 , wild-type mice succumbed to injection with FASL or anti-FAS antibody within 2.5-3 ( Fig. 2a ) or 3-4 h, respectively. Interestingly, these treatments killed XIAP-deficient mice considerably earlier (1-2 h for FASL, Fig. 2a ; ,2 h for anti-FAS antibody). Sick animals of both genotypes presented with abnormally elevated serum levels of the liver-associated transaminases ALT (alanine aminotransferase) and AST (aspartate aminotransferase; Fig. 2b ) and severe liver damage (Fig. 2g, h ). In contrast, loss of XIAP did not increase FAS-mediated apoptosis in thymocytes (type I cells; data not shown and ref. 24 ). Thus, XIAP is a critical attenuator of FAS-induced hepatocyte apoptosis.
To examine whether XIAP is the crucial discriminator between type I and type II FAS-induced apoptosis signalling, we generated BID/XIAP double-deficient mice, which exhibited no obvious abnormalities under unstressed conditions. As previously reported 6, 7 , BIDdeficient mice survived injection with FASL or anti-FAS antibody without developing signs of illness and showed no increase in serum ALT or AST levels or disruption of liver architecture ( Fig. 2 and Lysates from thymocytes and hepatocytes of the indicated genotype treated as described in a were examined using antibodies to XIAP, caspase-3 and HSP70 (loading control). Asterisk indicates crossreactive band. c, The binding of active caspase-3 to XIAP in liver lysates described in b was examined by immunoprecipitation (IP) with an antibody to XIAP followed by immunoblotting with antibodies to active caspase-3 or XIAP (loading control). d, Lysates as described in a were examined using antibodies to ICAD and HSP70 (loading control). , P 5 0.1133. b, Serum levels of ALT and AST in mice (a) after 120 min of FASL treatment (100 min for Xiap 2/2 mice). Horizontal bars indicate the mean; n, numbers of mice analysed. Asterisk, P 5 0.042 (ALT) or 0.022 (AST). c, Levels and processing of caspase-3, -7, -8, -9, BID (tBID exposed longer), MCL-1 and b-actin (loading control) in livers of FASLinjected mice (a) was examined by immunoblotting. d, Activation of caspase-3 and -7 in livers of FASL-injected mice (a) was examined by pull down with X-VAD-fmk followed by immunoblotting. e, Activation of caspase-3, -7, -8 and -9 in liver extracts from FASL-injected wild-type or Bid 2/2 mice (a) was examined as in d. Asterisk indicates a cross-reactive band. f, Fluorogenic measurement of effector caspase activity (DEVDase) in the livers of FASL-injected mice (a). Data represent means and s.e.m. from four independent measurements of two mice per genotype and time point. RFU, Relative fluorescence units; asterisk, P 5 0.02. g, h, Histology (g) and TUNEL staining (h) of liver sections from FASL-injected mice (a) killed as in b and controls. Images are representative of at least three mice per genotype and time point. Scale bars, 50 mm. Supplementary Fig. 4a) . In contrast, all BID/XIAP double-deficient animals succumbed to these treatments (albeit slightly later than wild-type mice, ,3-3.5 versus 2.5-3 h), presenting with abnormally elevated ALT/AST serum levels, severe liver damage and classical signs of hepatocyte apoptosis, including chromatin condensation and DNA fragmentation (Fig. 2a, b , g, h and Supplementary  Fig. 4a ). Immunoblotting demonstrated that FAS stimulation caused similar levels of caspase-8 processing in livers of mice of all genotypes, but caspase-9 and effector caspases were only activated in livers of the sensitive animals (wild type, Xiap 2/2 and Bid 2/2 Xiap 2/2 ), but not in those from the resistant Bid 2/2 mice (Fig. 2c) . This was confirmed by pull down of active caspase-8, -9, -3 and -7 with biotinylated X-VAD-fmk followed by immunoblotting with caspase-specific antibodies (Fig. 2d, e) and by fluorogenic effector caspase activity (DEVDase) assays (Fig. 2f) .
In accordance with our analyses of hepatocytes, BID deficiency protected pancreatic b-cells, which also undergo type II FAS-induced apoptosis 8 , from FASL, but concomitant loss of XIAP (in Bid 2/2 Xiap 2/2 mice) restored sensitivity ( Supplementary Fig. 5 ). Remarkably, pre-treatment with the caspase inhibitor qVD-OPh significantly (P 5 0.0042) protected Bid
2/2
Xiap 2/2 mice from FASLinduced fatal hepatitis and these animals contained lower ALT (P 5 0.078) and AST (P 5 0.024) levels in their sera and suffered less hepatocyte destruction compared to Bid
Xiap 2/2 animals that had only been injected with FASL ( Fig. 3a-d and Supplementary Fig. 4b ). As expected, pre-treatment with qVD-OPh inhibited FASL-induced processing of caspase-8 and subsequent activation of BID and caspase-3, -7 and -9 (Fig. 3e) . Thus, FAS stimulation kills BID/XIAP double-deficient hepatocytes through caspase-dependent apoptosis and not some caspase-independent process. Collectively, these results show that XIAP constitutes the critical regulator that discriminates between type I and type II FAS-induced apoptosis signalling.
An important question is whether the activation of caspase-9 by cytochrome c and APAF1 (apoptotic protease-activating factor 1) is necessary for type II FAS-induced apoptosis, or whether mitochondrial release of XIAP antagonists (for example, SMAC), leading to liberation of active effector caspases, is sufficient. Notably, 120 min after FASL injection, apoptotic nuclei (Fig. 2h ) and caspase-3 and -7 activation (Fig. 2c, d ) were readily detectable in livers from Bid
Xiap 2/2 mice, although their levels of cleaved caspase-9 were considerably lower than that of wild-type hepatocytes (Fig. 2c) . The caspase-9 processing seen in Bid 2/2 Xiap 2/2 livers (Fig. 2c ) might thus be a consequence of procaspase-9 cleavage by already activated effector caspases, indicating that caspase-9 may not be necessary for effector caspase activation in FAS-induced hepatocyte apoptosis. Consistent with this hypothesis, mice harbouring a mutation in cytochrome c that prevents apoptosome formation (and hence caspase-9 activation) showed normal sensitivity to FAS-induced hepatitis 25 , whereas combined loss of caspases-3 and -7 rendered cells resistant to FASL 26 . XIAP and related IAPs (cIAP1/2) are inhibited by SMAC 11, 12 and HTRA2 (also called OMI) proteins that are released from the mitochondria during apoptosis 9, 10 . SMAC mimetics are currently in development for cancer therapy and were shown to kill tumour cells (at least in part) by enhancing autocrine TNF-a-TNFR1 signalling [27] [28] [29] [30] . We examined the impact of the IAP inhibitor BV6 (ref. 27) on FASL-induced hepatocyte killing. Wild-type mice injected with BV6 plus FASL died significantly earlier than wild-type mice treated with FASL alone (Supplementary Fig. 6 ), indeed at a time comparable to FASL-injected Xiap 2/2 mice. Remarkably, all Bid 2/2 mice injected with FASL plus BV6 rapidly developed fatal hepatitis (Fig. 4a) , presenting with abnormally increased serum ALT and AST levels (Fig. 4b) and extensive hepatocyte destruction (Fig. 4c,  d and Supplementary Fig. 4c ), whereas all Bid 2/2 mice injected with FASL alone or BV6 alone remained healthy. Despite initial activation of caspase-8 in all FASL-treated animals, significant processing of effector caspases was only seen in Bid 2/2 mice that were injected with FASL plus BV6, but not in those treated with FASL or BV6 alone (Fig. 4e) . Pre-treatment with qVD-OPh protected Bid 2/2 mice from FASL-plus-BV6-induced fatal hepatitis (Fig. 4a) and this was reflected by lower ALT/AST serum levels compared to those seen in animals treated with FASL alone (Fig. 4b) . Histological examination and TdT-mediated dUTP nick end labelling (TUNEL) staining revealed normal liver architecture and only few apoptotic hepatocytes in mice treated with FASL, BV6 and qVD-OPh combined (Fig. 4c, d and Supplementary Fig. 4c ). This demonstrates that the combination of FASL plus BV6 triggers caspase-dependent hepatocyte apoptosis.
BV6 treatment could theoretically promote FASL-induced hepatocyte killing by blocking cIAP1 and/or cIAP2, which would be expected to require autocrine/paracrine TNF-a-TNFR1 signalling [27] [28] [29] [30] . Treatment with FASL, BV6 or both had, however, no impact on the levels of TNF-a in livers (Supplementary Figs 6c and 7c) and, pertinently, TNFa-neutralizing antibodies had no effect on FASL-plus-BV6-induced hepatocyte destruction in Bid 2/2 mice ( Supplementary Fig. 7a , b) although they could prevent TNF-a-induced killing of L929 cells and lipopolysaccharide (LPS)-plus-galactosamine (GalN)-induced fatal hepatitis, a TNF-a-TNFR1-dependent process 4 ( Supplementary  Fig. 8 ). Thus, BV6 does not need to activate TNF-TNFR1 signalling to promote FASL-induced hepatocyte killing, but functions by blocking the anti-apoptotic activity of XIAP. The notion that XIAP rather than cIAP1/cIAP2 is the critical target of BV6 in FAS-induced hepatocyte apoptosis is underscored by the finding that only Xiap 2/2 mice ( Fig. 2a and Supplementary Fig. 6a ), but not mice lacking cIAP1, cIAP2 or both in their livers, succumbed more rapidly to FASL-induced hepatitis than wild-type animals (not shown). The importance of XIAP in regulating FAS-induced apoptosis predicts that the endogenous IAP antagonists SMAC and/or HTRA2 have critical roles in this process. Because Bid
Xiap 2/2 mice succumb to FASL-induced hepatitis more slowly than wild-type animals, apoptosis inhibitors in addition to XIAP, such as ML-IAP 10 , may contribute to the regulation of this process. Finally, although IAP inhibition represents a promising strategy for cancer therapy, our data indicate that IAP inhibitors should be used with caution in combination with liver toxic chemotherapy or patients with underlying liver conditions.
METHODS SUMMARY
FASL-induced hepatitis. Mice were injected intravenously with 0.25 mg per kg body weight recombinant soluble FASL (Flag-tagged FASL, Alexis Biochemicals) crosslinked with 2 mg anti-Flag antibody (M2, Sigma-Aldrich) per mg FASL. The pan-caspase inhibitor qVD-OPh (MP Biomedicals) was injected at a concentration of 20 mg per kg body weight intraperitoneally 30 min before FASL administration. The SMAC mimetic BV6 (a gift from Genentech) was injected intraperitoneally (10 mg per kg body weight) 30 min before FASL administration. Mice were killed at various time points, bled for serum analysis of the liverassociated transaminases ALT and AST and the livers were removed for biochemical and histological analyses. Statistical analyses were performed applying a two-tailed unpaired Student's t-test. Statistical analysis of animal survival was performed using a Log-rank (Mantel-Cox) test.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
